The document this correction applies to
Timely disclosureWhat was corrected and how
A subsequent correction by the company to the contents of an already published filing.
Notice Concerning Domestic Integration of the Acugo® Production System Following Closure of Minaris’ U.S. Plant
Open the original documentSpecifically, the original notice stated: “We have entered into a manufacturing outsourcing agreement with JCR Pharmaceuticals, Inc. concerning product manufacturing and are proceeding with the establishment of a manufacturing system at the company.”
Entered into an agreement with JCR Pharmaceuticals, Inc. for commissioned and outsourced product manufacturing
Entered into a trial manufacturing agreement with JCR Pharmaceuticals, Inc. aimed at the commercial manufacturing of this product
This matter will have no material impact on results for the current fiscal year. It will also have no material impact on product supplies to patients or the company’s sales.
Because part of the information disclosed required correction
| Item | Details |
|---|---|
| Disclosure subject to correction | Notice Concerning Domestic Integration of the Acugo® Production System Following Closure of Minaris’ U.S. Plant |
| Original disclosure date | 31 August 2026 |
| Location of correction | Specifically, the original notice stated: “We have entered into a manufacturing outsourcing agreement with JCR Pharmaceuticals, Inc. concerning product manufacturing and are proceeding with the establishment of a manufacturing system at the company.” |
| Details of correction | Entered into an agreement with JCR Pharmaceuticals, Inc. for commissioned and outsourced product manufacturing → Entered into a trial manufacturing agreement with JCR Pharmaceuticals, Inc. aimed at the commercial manufacturing of this product |
| Reason for correction | Because part of the information disclosed required correction |
| Impact on Business Performance | This matter will have no material impact on results for the current fiscal year. It will also have no material impact on product supplies to patients or the company’s sales. |
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explained that the notice disclosed on 31 August 2026 contained items requiring correction, but did not provide specific reasons.